Corporate Information
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA's exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from UCB, S.A. for CIMZIA® (certolizumab pegol). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.
Access XOMA 2009 Proxy Materials
Recent News
Feb 9, 2010
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
Feb 3, 2010
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9Events
$0.02
